Kits, compositions and methods for detecting a biological condition
The present invention provides kits, apparatus and methods for determining a biological condition in a mammalian subject, the method includes incubating a specimen from a patient with at least one composition in a kit for a predetermined period of time to form at least one reaction product, when the subject has said biological condition, and receiving an indication of the at least one reaction product responsive to at least one reporter element in the kit thereby providing the indication of the biological condition in the subject.
1. A test cartridge for assaying for possible infection or sepsis in a subject, comprising a single use microfluidic cartridge that is adapted to receive a blood sample from a subject, the microfluidic cartridge comprising:
a) a sample composition chamber adapted for receiving a blood sample from a subject;
b) a first pre-filled microfluidic blister comprising an antibody mixture comprising fluorescently tagged CD64 and fluorescently tagged CD163 antibodies;
c) a second pre-filled microfluidic blister comprising a cell lysis reagent;
d) a third pre-filled microfluidic blister comprising fluorescently tagged beads comprising two fluorescent tags, wherein at least one of the two fluorescent tags is different than the fluorescently tagged CD64 and fluorescently tagged CD163 antibodies;
d) a treatment compartment adapted for fluid mixing, wherein the treatment compartment is in fluid communication with the sample composition chamber, the first pre-filled microfluidic blister, the second pre-filled microfluidic blister, and the third pre-filled microfluidic blister;
e) a pump connected to the treatment compartment; and
f) an evaluation chamber fluidly connected to the treatment chamber and comprising a reading zone.
2. A Cartridge Handling Unit (CHU) for detection of possible infection or sepsis in a subject, the CHU adapted to receive a test cartridge and pre-programmed to perform at least the following steps:
a) pressing a first blister of the test cartridge thereby releasing an antibody mixture and permitting it to contact with a blood sample, wherein the antibody mixture comprises fluorescently tagged CD64 and fluorescently tagged CD163 antibodies;
b) allowing the blood sample and the antibody mixture to contact for a predetermined time thereby fluorescently tagging blood cells in the blood sample;
c) pressing a second blister of the test cartridge thereby releasing fluorescently tagged beads comprising two fluorophores to contact the blood sample and antibody mixture, wherein at least one of the two fluorescent tags is different than the fluorescently tagged CD64 and fluorescently tagged CD163 antibodies;
d) individually flowing tagged blood cells and tagged beads through a reading zone;
e) exciting the fluorescent tags of the beads and of the antibodies;
f) measuring fluorescent signals of the fluorescently tagged blood cells and of the fluorescently tagged beads simultaneously; and
g) using the measuring to provide an indication of the possibility of infection or sepsis in the subject.
3. The CHU of claims 2 , wherein the test cartridge further comprises a pump or an air blowing element.
4. The CHU of claims 3 , wherein the contact between the bloods sample and the antibody mixture is facilitated using the pump or the air blowing element.
5. The microfluidic cartridge of claims 1 , wherein the pump is a bellow pump.
6. The microfluidic cartridge of claim 1 , wherein the microfluidic cartridge is valveless.
7. The microfluidic cartridge of claim 1 , wherein a volume of any of the blisters is from about 1 microliter to 1000 microliters.
8. The microfluidic cartridge of claim 1 , wherein a volume of the blood sample is about 10 microliters.
9. The CHU of claim 2 , wherein the CHU is pre-programmed to perform the steps in less than 15 minutes.
10. The microfluidic cartridge of claim 1 , wherein the microfluidic cartridge further comprises a tortuous shaped channel.
11. The microfluidic cartridge of claim 1 , wherein the fluorescently tagged beads comprise Starfire Red.
12. The microfluidic cartridge of claim 1 , wherein the blood sample is whole blood.
13. The microfluidic cartridge of claim 1 , wherein the blood sample comprises erythrocytes or leukocytes, and wherein the leukocytes comprise lymphocytes or neutrophils.
14. The microfluidic cartridge of claim 1 , wherein the blood sample comprises leukocytes.
15. The CHU of claim 2 , wherein the CHU is pre-programmed to press a third blister of the test cartridge thereby releasing a cell lysis reagent and permitting the cell lysis reagent to contact the blood sample and the antibody mixture.
16. The CHU of claim 15 , wherein pressing the third blister occurs after pressing the first blister and before pressing the second blister.
17. The microfluidic cartridge of claim 1 , wherein the cell lysis reagent comprises ammonium chloride.
18. The microfluidic cartridge of claim 1 , wherein the antibodies are murine monoclonal antibodies.
19. The CHU of claim 2 , wherein using the measuring to provide an indication comprises employing at least one of cross-correlation algorithm, boxcar averaging algorithm, filtering algorithm or minimum mean square error fit.
20. The CHU of claim 2 , wherein the CHU is pre-programmed to determine a type of the blood cells.
21. The CHU of claim 2 , wherein the test cartridge is valveless.
22. The CHU of claim 2 , wherein a volume of any of the blisters is from about 1 microliter to 1000 microliters.
23. The CHU of claim 2 , wherein a volume of the blood sample is about 10 microliters.
24. The CHU of claim 2 , wherein the test cartridge comprises a tortuous shaped channel.
25. The CHU of claim 2 , wherein the fluorescently tagged beads comprise Starfire Red.
26. The CHU of claim 15 , wherein the cell lysis reagent comprises ammonium chloride.
27. The CHU of claim 2 , wherein the antibodies are murine monoclonal antibodies.